Experimental regimen targeting the ependyma slows disease progression in four patitents with ALS
|Citation: Payne AG. ,’Experimental regimen targeting the ependyma slows disease progression in four patitents with ALS,’ Med Hypotheses (2009), doi:10.1016/j.mehy.2008.12.032
Dr. Anthony G. Payne*
In this paper the author proposes that at least some forms of sporadic ALS (amyotrophic lateral sclerosis) arise due to the effects of neurotoxic compounds synthesized by defective ependymal cells in the brain. These cells produce cerebrospinal fluid (CSF) that is laden with neurotoxic compounds that bring about motor neuron die-off. Evidence is garnered from various animal studies to demonstrate the toxicity of CSF taken from ALS patients and by virtue of the proposed mechanism (defective ependymal cells). In addition, a regimen created by the author is introduced; a regimen that has been used by four (4) sporadic ALS patients since 2005 resulting in what appears to be a slowing of disease progression. All four patients have significantly outlived best estimates of their survival tendered by their neurologists. 2009 Published by Elsevier Ltd.
Posted on May 21, 2009, in Amyotrophic Lateral Sclerosis (ALS) and tagged ALS, ALS patients, Amyotrophic Lateral Sclerosis, Ependyma, extending life in ALS, hope for ALS, improving function in ALS, Lou Gehrig's disease, regimen for ALS, reversing ALS, slows ALS progression, sporadic ALS. Bookmark the permalink. Comments Off on Experimental regimen targeting the ependyma slows disease progression in four patitents with ALS.